RecruitingPhase 2NCT06891040
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Enrollment
114 participants
Start Date
Apr 28, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A multicenter, randomized, double-blind, vehicle controlled phase II clinical study
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);
- The age requirement for signing the ICF is 18 years old or above, with no gender restrictions;
- During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria;
Exclusion Criteria5
- Skin damage or abnormalities that may affect the evaluation of the administration site of the investigational drug;
- Skin diseases that are contraindicated in research or affect the evaluation of drug administration sites, including but not limited to psoriasis, acne, and skin cancer;
- Suffering from autoimmune diseases other than AD, such as inflammatory bowel disease and rheumatoid arthritis, and the researchers believe that this disease will be detrimental to the evaluation of this study;
- Current history of or presence of lymphoproliferative disorders, or signs or symptoms suggesting possible lymphoproliferative disorders, including lymphadenopathy or splenomegaly;
- Various malignant tumors, or any history of malignant tumors within the past 5 years prior to screening (excluding completely resected cervical carcinoma in situ, non metastatic squamous cell carcinoma, basal cell carcinoma, or papillary thyroid carcinoma);
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGVC005 Placebo group
VC005 Placebo group with Local topical application
DRUGVC005 groups
VC005 group with Local topical application
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06891040
Related Trials
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT006058781 location
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT0639791116 locations
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT065994111 location
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT076458204 locations